Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile

By Reuters News

- Kodiak Sciences Inc. KOD.O:

  • ZENKUDA AND TABIRAFUSP-TED MEET PRIMARY ENDPOINTS IN PIVOTAL DAYBREAK TRIAL IN WAMD, WITH ZENKUDA DEMONSTRATING A POTENTIAL NEW STANDARD-OF-CARE PROFILE WITH STRONG IMMEDIACY AND SUSTAINED CLINICAL EFFECT WITH MAJORITY OF PATIENTS ON 24-WEEK DOSING INTERVAL USING STRICT TREAT-TO-DRYNESS REAL WORLD RETREATMENT CRITERIA.

  • KODIAK SCIENCES - ZENKUDA BLA PLANNED FOR Q4 2026 TO INCLUDE FIVE POSITIVE PHASE 3 STUDIES

  • KODIAK SCIENCES INC. - ZENKUDA AND TABIRAFUSP-TED DEMONSTRATED SAFETY CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AFLIBERCEPT

Further company coverage: KOD.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk